Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Carmat To Launch Total Artificial Heart In Early 2021

Executive Summary

After years of setbacks, the company will launch its device in Europe as a bridge to transplant in heart failure patents.

You may also be interested in...



Pivotal Trial Of Carmat’s Total Artificial Heart Delayed

Carmat suspended the production of its Total Artificial Heart while it strengthens certain manufacturing processes.

FDA Updates Class I Recall Alert For SynCardia's Bridge-To-Transplant System

SynCardia Systems' Freedom Driver System was subject to a class I recall last year, and now US FDA has updated its concerns about a component of the firm's Temporary Total Artificial Heart based on post-approval study data, and is asking that malfunctioning drivers be returned to the manufacturer.

INTERVIEW: Carmat stays on the beat with potential 2016 artificial heart CE mark

Carmat has taken another step towards approval of its biocompatible artificial heart after developing a portable console that has allowed one patient implanted with the system to return home.

Topics

Related Companies

UsernamePublicRestriction

Register

MT143255

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel